Looking for a new broker?
Lisata Therapeutics, Inc. stock is up 14.22% since 30 days ago. The next earnings date is Mar 28, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 30.23% of the previous 42 December’s closed higher than November.
Caladrius Biosciences, Inc. focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia.
